Subscribe

Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)

SEK65.10 +0.10 (+0.15%)
SE STO Healthcare Medical - Pharmaceuticals
Address Bryggargatan 10 111 21
Stockholm, AB, SE
CEO Staffan Strömberg
Website ibtherapeutics.com
IPO 2016-03-29
ISIN SE0008015259

Explore sections of this company profile

Description

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK65.10 +0.10 (+0.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10.4K
Beta
0.37
Float Shares
11.23M
Free Float %
86.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-3.06% -10.17% +8.34% -2.00% -8.02% +8.23% -7.86% +15.42% -51.70% +62.76% -7.81%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
65.10
DCF (Unlevered) 8.27 -87.3%
DCF (Levered) 10.69 -83.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-0.63
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Pharmaceuticals: +7.8%
    -100.0%
  • ✗
    EPS growth Medical - Pharmaceuticals: +20.2%
    +52.4% ★ Q1'26: -37.1% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    —
  • ✗
    EBIT margin Medical - Pharmaceuticals: +6.8%
    —
  • ✓
    ROIC Medical - Pharmaceuticals: +6.1%
    — Q1'26: +187.7% (vs Q1'25)
  • ✓
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.0% Q1'26: +0.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.47) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 8.27 Current price: 65.10
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana. 		Dec 2029
1 Rev. Ana.
1 EPS Ana. 		Dec 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
12.0K
est: 133.70M (-100.0%)
77.0K
est: 359.40M (-100.0%)
4.0K
est: 359.40M (-100.0%)
—
732.00M
732.00M – 732.00M
400.00M
400.00M – 400.00M
-45.4% YoY
684.00M
684.00M – 684.00M
+71.0% YoY
927.00M
927.00M – 927.00M
+35.5% YoY
1.07B
1.07B – 1.07B
+15.5% YoY
EBITDA
-64.34M
est: 26.74M (-340.6%)
11.55M
est: 71.88M (-83.9%)
-136.91M
est: 71.88M (-290.5%)
-65.17M
146.40M
146.40M – 146.40M
80.00M
80.00M – 80.00M
-45.4% YoY
136.80M
136.80M – 136.80M
+71.0% YoY
185.40M
185.40M – 185.40M
+35.5% YoY
214.20M
214.20M – 214.20M
+15.5% YoY
EBIT
-65.45M
est: -26.74M (-144.8%)
-123.07M
est: -71.88M (-71.2%)
-136.91M
est: -71.88M (-90.5%)
-65.17M
-146.40M
-146.40M – -146.40M
-80.00M
-80.00M – -80.00M
+45.4% YoY
-136.80M
-136.80M – -136.80M
-71.0% YoY
-185.40M
-185.40M – -185.40M
-35.5% YoY
-214.20M
-214.20M – -214.20M
-15.5% YoY
Net Income
-65.45M
est: -143.07M (+54.3%)
-123.07M
est: -33.27M (-269.9%)
-136.91M
est: -33.27M (-311.4%)
-65.17M
est: -97.94M (+33.5%)
-90.53M
-90.53M – -90.53M
+7.6% YoY
195.34M
195.34M – 195.34M
+315.8% YoY
97.26M
97.26M – 97.26M
-50.2% YoY
215.14M
215.14M – 215.14M
+121.2% YoY
252.72M
252.72M – 252.72M
+17.5% YoY
SGA
1.02M
est: 136.38B (-100.0%)
14.58M
est: 366.59B (-100.0%)
19.30M
est: 366.59B (-100.0%)
20.15M
746.65B
746.65B – 746.65B
408.01B
408.01B – 408.01B
-45.4% YoY
697.69B
697.69B – 697.69B
+71.0% YoY
945.56B
945.56B – 945.56B
+35.5% YoY
1.09T
1.09T – 1.09T
+15.5% YoY
EPS
-5.83
est: -10.62 (+45.1%)
-9.95
est: -2.47 (-302.8%)
-10.16
est: -2.47 (-311.3%)
-4.84
est: -7.27 (+33.4%)
-6.72
-6.72 – -6.72
+7.6% YoY
14.50
14.50 – 14.50
+315.8% YoY
7.22
7.22 – 7.22
-50.2% YoY
15.97
15.97 – 15.97
+121.2% YoY
18.76
18.76 – 18.76
+17.5% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 C- 1/5 3/5 1/5 1/5 1/5 1/5 1/5
Ownership data is not available for this company yet.

Executive team

Top executives
Shares Outstanding
13.02M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Staffan Stromberg Chief Executive Officer 5M male
Anders Kronstrom Chief Operating Officer 500.0K male
Anders Kronström Chief Operating Officer 500.0K male
Maria Ekdahl Chief Financial Officer — female
Sanjiv Sharma Head of Medical Affairs — male
Thomas J. Schnitzer Chief Scientific Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals